Revenue
$3.33B
Fiscal year ended 2026-06-30Operating income
$1.25B
Fiscal year ended 2026-06-30Free cash flow
$1.01B
Fiscal year ended 2026-06-30VERTEX PHARMACEUTICALS INC / MA (VRTX) reported revenue of $3.33B and net income of $1.10B for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from VERTEX PHARMACEUTICALS INC / MA’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.33B | $2.99B | $3.19B | $3.08B | $2.96B | $2.77B | $2.91B | $2.77B | $2.65B | $2.69B |
| Cost of revenue | $489.20M | $392.80M | $466.00M | $414.80M | $407.50M | $363.00M | $423.40M | $392.60M | $371.90M | $342.60M |
| Gross profit | $2.84B | $2.59B | $2.72B | $2.66B | $2.56B | $2.41B | $2.49B | $2.38B | $2.27B | $2.35B |
| Operating income | $1.25B | $1.14B | $1.21B | $1.19B | $1.15B | $630.10M | $1.03B | $1.12B | -$3.51B | $1.14B |
| Net income | $1.10B | $1.03B | $1.19B | $1.08B | $1.03B | $646.30M | $913.00M | $1.05B | -$3.59B | $1.10B |
| Research & development | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Weighted-average diluted shares | shares 255.20M | shares 256.30M | Unavailable | shares 257.60M | shares 258.90M | shares 259.50M | Unavailable | shares 261.00M | shares 258.10M | shares 261.10M |
| Pretax income | $1.39B | $1.25B | $1.33B | $1.30B | $1.28B | $730.40M | $1.14B | $1.22B | -$3.39B | $1.28B |
| Income tax expense | $292.00M | $221.50M | $139.90M | $215.90M | $250.10M | $84.10M | $223.50M | $178.70M | $202.40M | $179.50M |
| Diluted EPS | $4.31 | $4.02 | Unavailable | $4.20 | $3.99 | $2.49 | Unavailable | $4.01 | $-13.92 | $4.21 |
| Selling, general & administrative | $582.20M | $493.70M | $487.00M | $445.10M | $424.60M | $396.40M | $377.60M | $371.80M | $372.20M | $342.70M |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $6.14B | $5.49B | $5.08B | $4.94B | $4.97B | $4.67B | $4.57B | $5.24B | $4.58B | $9.16B |
| Total assets | $27.42B | $26.48B | $25.64B | $24.86B | $24.04B | $22.88B | $22.53B | $22.24B | $20.13B | $23.92B |
| Current assets | $12.54B | $11.73B | $11.20B | $10.57B | $10.43B | $10.01B | $9.60B | $9.80B | $8.94B | $13.29B |
| Total liabilities | $7.18B | $7.12B | $6.98B | $7.54B | $6.86B | $6.38B | $6.12B | $6.61B | $5.36B | $5.37B |
| Current liabilities | $3.94B | $3.88B | $3.86B | $4.48B | $4.14B | $3.78B | $3.56B | $3.97B | $3.55B | $3.80B |
| Total equity incl. NCI | $20.25B | $19.36B | $18.67B | $17.32B | $17.18B | $16.50B | $16.41B | $15.63B | $14.77B | $18.55B |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $1.77B | $1.77B | $1.69B | $1.63B | $1.50B | $1.36B | $1.21B | $1.08B | $914.60M | $813.10M |
| Accounts receivable | $2.13B | $2.00B | $2.05B | $1.95B | $1.89B | $1.81B | $1.61B | $1.75B | $1.66B | $1.79B |
| Goodwill | $1.09B | $1.09B | $1.09B | $1.09B | $1.09B | $1.09B | $1.09B | $1.09B | $1.09B | $1.09B |
| Long-term debt | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts payable | $429.50M | $489.30M | $461.70M | $420.30M | $442.30M | $445.00M | $413.00M | $395.80M | $327.90M | $351.40M |
Cash flow
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.13B | $1.43B | $498.00M | $1.24B | $1.07B | $818.90M | $584.60M | $1.37B | -$3.75B | $1.31B |
| Capital expenditures | $112.20M | $133.40M | $149.40M | $101.80M | $145.70M | $40.70M | $92.60M | $67.70M | $69.00M | $68.40M |
| Investing cash flow | -$45.80M | -$431.90M | -$288.10M | -$117.00M | -$484.50M | -$55.80M | -$821.90M | -$348.00M | -$463.70M | -$2.14B |
| Financing cash flow | -$426.70M | -$538.80M | -$77.20M | -$1.15B | -$349.20M | -$680.40M | -$391.30M | -$387.50M | -$358.60M | -$357.50M |
| Net change in cash | $649.20M | $417.10M | $140.00M | -$34.20M | $296.60M | $113.20M | -$675.90M | $657.10M | -$4.58B | -$1.20B |
| Stock-based compensation | $170.20M | $166.40M | $157.60M | $194.90M | $167.30M | $166.10M | $167.80M | $184.60M | $154.20M | $191.90M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | $469.50M | $336.90M | $128.40M | $1.07B | $391.80M | $426.10M | $417.90M | $307.70M | $320.30M | $131.20M |
| Depreciation & amortization | $56.50M | $55.90M | $55.70M | $54.00M | $51.70M | $48.40M | $46.50M | $53.20M | $54.00M | $53.50M |
Derived
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $1.01B | $1.29B | $348.60M | $1.14B | $927.40M | $778.20M | $492.00M | $1.30B | -$3.82B | $1.24B |
| Gross margin | 85.3% | 86.8% | 85.4% | 86.5% | 86.3% | 86.9% | 85.5% | 85.8% | 85.9% | 87.3% |
| Operating margin | 37.4% | 38.1% | 37.8% | 38.6% | 38.8% | 22.7% | 35.2% | 40.3% | -132.9% | 42.4% |
| FCF margin | 30.4% | 43.3% | 10.9% | 37.0% | 31.3% | 28.1% | 16.9% | 47.0% | -144.5% | 46.0% |
| SBC / revenue | 5.1% | 5.6% | 4.9% | 6.3% | 5.6% | 6.0% | 5.8% | 6.7% | 5.8% | 7.1% |
| Current ratio | 3.19x | 3.02x | 2.90x | 2.36x | 2.52x | 2.65x | 2.69x | 2.47x | 2.52x | 3.50x |
| Revenue YoY growth | 12.5% | 7.8% | 9.5% | 11.0% | 12.1% | 3.0% | 15.7% | 11.6% | 6.1% | 13.3% |
| Net margin | 33.0% | 34.5% | 37.3% | 35.2% | 34.8% | 23.3% | 31.4% | 37.7% | -135.8% | 40.9% |
| R&D / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | 3.4% | 4.5% | 4.7% | 3.3% | 4.9% | 1.5% | 3.2% | 2.4% | 2.6% | 2.5% |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 21.0% | 17.7% | 10.5% | 16.6% | 19.5% | 11.5% | 19.7% | 14.6% | Unavailable | 14.0% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VRTX in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-02-13View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-06View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.